Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| VCEL | 8-K | bullish | 7/10 | Vericel reported Q1 2026 total revenue of $68.4M (+30% YoY), beating the $63.6M consensus, and a GAAP net loss of $0.12/ | May 7, 2026 |
| ASND | 6-K | bullish | 8/10 | Ascendis Pharma reported Q1 2026 revenue of €247M (up 144% YoY from €101M), driven by YORVIPATH sales of €197M. The comp | May 7, 2026 |
| VTRS | 8-K | bullish | 7/10 | Viatris reported Q1 2026 adjusted EPS of $0.59, 18% above consensus of $0.50, and revenue of $3.52B, 5% above consensus | May 7, 2026 |
| ASND | 6-K | bullish | 7/10 | Ascendis Pharma reported Q1 2026 revenue of €246.6M (+144% YoY), driven by YORVIPATH sales tripling to €196.9M. Operatin | May 7, 2026 |
| VCEL | PRESS-RELEASE | bullish | 8/10 | Vericel reported Q1 2026 revenue of $68.4M (+30% YoY) and GAAP EPS of -$0.12 (vs consensus -$0.16, a 25% beat on the los | May 7, 2026 |
| EVAX | 6-K | neutral | 3/10 | Evaxion reported Q1 2026 results with net loss widening to $3.6M from $1.6M due to lower financial income, while operati | May 7, 2026 |
| CRDL | 6-K | bullish | 6/10 | Cardiol Therapeutics announced that its Phase II MAvERIC results for CardiolRx in recurrent pericarditis were accepted f | May 7, 2026 |
| LNTH | 8-K | mixed | 6/10 | Lantheus reported Q1 2026 revenue of $377.3M (beat consensus $354.4M) and adjusted EPS of $1.46 (beat $1.23), but adjust | May 7, 2026 |
| ZURA | 8-K | neutral | 3/10 | Zura Bio reported Q1 2026 net loss of $24.2M ($0.22/share), wider than consensus estimate of -$0.17 and the year-ago los | May 7, 2026 |
| VERA | 8-K | neutral | 4/10 | Vera Therapeutics reported Q1 2026 results with a net loss of $1.69 per share, wider than the $0.81 loss in Q1 2025, dri | May 7, 2026 |
| BDTX | 8-K | neutral | 4/10 | Black Diamond Therapeutics reported Q1 2026 EPS of -$0.16, beating consensus of -$0.21, with $0 revenue as expected. Net | May 7, 2026 |
| RAPP | 8-K | mixed | 6/10 | Rapport Therapeutics reported Q1 2026 results with a net loss of $19.9M ($0.42 per share), beating the $-0.56 consensus | May 7, 2026 |
| CRL | 8-K | bearish | 6/10 | CRL reported Q1 2026 non-GAAP EPS of $2.06, a 12.0% YoY decline from $2.34, and revenue of $995.8M (+1.2% reported, -1.5 | May 7, 2026 |
| RMTI | 8-K | neutral | 2/10 | Rockwell Medical filed an 8-K indicating that an updated corporate investor presentation was made available on May 7, 20 | May 7, 2026 |
| IRWD | 8-K | bullish | 7/10 | Ironwood Pharmaceuticals reported a massive Q1 2026 beat with GAAP EPS of $0.24 vs $0.07 consensus (+243%) and revenue o | May 7, 2026 |
| TRDA | PRESS-RELEASE | mixed | 6/10 | Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M ($0.95/share), beating consensus EPS of -$1.06 b | May 7, 2026 |
| SRRK | 8-K | mixed | 6/10 | Scholar Rock reported Q1 2026 net loss of $0.83/share (vs consensus $0.78 miss), with no revenue. The key positive is FD | May 7, 2026 |
| ZTS | 8-K | bearish | 7/10 | Zoetis Q1 2026 adjusted EPS of $1.53 missed consensus of $1.62 (-5.6%), and FY2026 guidance was lowered to revenue of $9 | May 7, 2026 |
| CLYM | 8-K | bullish | 6/10 | Climb Bio reported Q1 2026 EPS of -$0.20, beating consensus of -$0.26 by 23%, and reduced net loss to $13.7M from $20.8M | May 7, 2026 |
| GLUE | 8-K | mixed | 5/10 | Monte Rosa reported Q1 2026 collaboration revenue of $4.2M (down 95% YoY from $84.9M) and a net loss of $44.5M vs $46.9M | May 7, 2026 |
| NAMSW | 8-K | bullish | 6/10 | NewAmsterdam Pharma reported Q1 2026 revenue of $3.0M (flat YoY) and a net loss of $48.4M, widening from $39.5M. The key | May 7, 2026 |
| FHTX | 8-K | neutral | 3/10 | Foghorn Therapeutics reported Q1 2026 collaboration revenue of $3.3M (down from $6.0M YoY), net loss of $19.9M (vs $18.8 | May 7, 2026 |
| INSM | 8-K | bullish | 6/10 | Insmed reported Q1 2026 total revenue of $306.0M (up 230% YoY, driven by BRINSUPRI launch) and a net loss of $163.6M ($0 | May 7, 2026 |
| GPRE | 8-K | mixed | 7/10 | Green Plains reported Q1 2026 EPS of $0.42, far above the -$0.01 consensus, with adjusted EBITDA of $71.5M including $55 | May 7, 2026 |
| FENC | PRESS-RELEASE | neutral | 1/10 | Fennec Pharmaceuticals Inc. announced it will report its Q1 2026 results on May 14, 2026. | May 7, 2026 |
| NUVL | 8-K | neutral | 4/10 | Nuvalent reported Q1 2026 results with a net loss of $109.3M ($1.39/share), wider than the $84.6M loss in Q1 2025, as R& | May 7, 2026 |
| STTK | 8-K | neutral | 3/10 | Shattuck Labs reported Q1 2026 net loss of $0.13 per share, slightly better than consensus of -$0.14, but the company re | May 7, 2026 |
| STTK | PRESS-RELEASE | bullish | 5/10 | Shattuck Labs reported Q1 2026 EPS of -$0.12, beating consensus of -$0.13 by 9.1%, with zero revenue as expected. The co | May 7, 2026 |
| LODE | EFFECT | neutral | 4/10 | Comstock Inc.'s shelf registration statement (S-3) became effective on May 6, 2026, covering up to $200 million in secur | May 7, 2026 |
| VOR | EFFECT | neutral | 3/10 | Vor Biopharma's S-3 registration statement (File No. 333-295346) became effective on May 6, 2026, enabling the resale of | May 7, 2026 |